The present invention relates to a novel 1,4-disubstituted piperazine derivatives
of Formula I,
##STR1##
and their pharmaceutically acceptable acid addition salts having excellent uro-selective
1-adrenoceptor antagonistic activity exceeding those of previously
described compounds. The compounds of the present invention hold promise for treating
the symptoms of benign prostatic hyperplasia (BPH). The invention also relates
to methods for making the novel compounds, pharmaceutical compositions containing
the compounds, and method of treating the symptoms of benign prostatic hyperplasia
using the compounds.
